Telisotuzumab vedotin
- Generic Name
- Telisotuzumab vedotin
- Drug Type
- Biotech
- CAS Number
- 1714088-51-3
- Unique Ingredient Identifier
- 976X9VXC3Z
- Background
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06568939
- Locations
- 🇺🇸
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha, Nebraska, United States
🇺🇸Cancer Care Associates Of York /ID# 270971, York, Pennsylvania, United States
🇺🇸SCRI Oncology Partners /ID# 270162, Nashville, Tennessee, United States
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06093503
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT05513703
- Locations
- 🇫🇷
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267, Bron, Rhone, France
🇦🇺Monash Medical Centre /ID# 247679, Clayton, Victoria, Australia
🇫🇷CHU Lille - Hôpital Albert Calmette /ID# 246263, Lille, Hauts-de-France, France
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 698
- Registration Number
- NCT04928846
- Locations
- 🇺🇸
University of Alabama at Birmingham - Main /ID# 247074, Birmingham, Alabama, United States
🇺🇸Ironwood Cancer & Res Ctr /ID# 262446, Chandler, Arizona, United States
🇺🇸Mayo Clinic Arizona /ID# 255858, Phoenix, Arizona, United States
Expanded Access to Telisotuzumab Vedotin
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04830202
- Locations
- 🇺🇸
Oncology & Hematology Specialist /ID# 248083, Mountain Lakes, New Jersey, United States
🇺🇸Sutter Medical Group /ID# 254816, Sacramento, California, United States
🇦🇺Western Heamatology and Oncology Clinics /ID# 243364, West Perth, Western Australia, Australia
Lung-MAP S1400K: c-MET Positive
- Conditions
- Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC V7
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 28
- Registration Number
- NCT03574753
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT03539536
- Locations
- 🇺🇸
Veterans Healthcare System /ID# 215602, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT03311477
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 166939, Chuo-ku, Tokyo, Japan
🇯🇵Shizuoka Cancer Center /ID# 166940, Sunto-gun, Shizuoka, Japan
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 237
- Registration Number
- NCT02099058
- Locations
- 🇺🇸
Washington University-School of Medicine /ID# 143798, Saint Louis, Missouri, United States
🇺🇸Summit Medical Group-Florham Park /ID# 217651, Florham Park, New Jersey, United States
🇺🇸Montefiore Medical Park at Eastchester /ID# 218445, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.